<DOC>
	<DOC>NCT02151240</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of Foscarnet Sodium and Sodium Chloride Injection in patients with herpes zoster, and observe incidence of Postherpetic neuralgia</brief_summary>
	<brief_title>Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster</brief_title>
	<detailed_description />
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<criteria>1.Patients with clinical diagnosis of Herpes Zoster, and able to be enrolled into the study ≤ 72 hours from appearance of rash; 2.1865 years old, men and women; 3.VAS score≥4; 4.Patients haven't receive any antiviral medication before enrollment; 5.Patients able to understand the study procedures, agree to participate and give written consent. 1. Patients with history of allergy to Foscarnet Sodium or Acyclovir; 2. Other combined infection (bacteria, fungi) 3. Severe decline in immune function, or longterm use of corticosteroid and immunosuppressor 4. Serious liver or renal function abnormalities (Aspartate Transaminase(AST) or alanine transaminase(ALT) ≥ 2.5x upper limits of normal(ULN), Creatinine(Cr) or Blood urea nitrogen(BUN)≥ 1x ULN) 5. Women who are pregnant or lactating, and women of childbearing potential failed to use an adequate method of contraception to avoid pregnancy; 6. Patients using other antiviral drugs; 7. Longterm use of nonsteroid antiinflammatory drug, tricyclic antidepressant, antiepileptic drugs or analgesic 8. Current malignant tumor; 9. Patients investigators consider as inappropriate to participate in the study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>herpes zoster, Foscarnet Sodium, Acyclovir, Postherpetic neuralgia</keyword>
</DOC>